• potent
  • Xanomeline tartrate [3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-l-methylpyridine tartrate], also known as LY246708 tartrate, is a potent and selective M1 agonist that crosses the blood brain barrier in animals and is orally bioavailable (Eli Lilly, unpublished data). (springer.com)
  • exposure
  • Cardioinhibition persisted throughout the 5-minute exposure to cholinergic agonists in sinoatrial preparations from the 12th and l8th incubation days whereas automaticity recovered completely within 1 to 2 minutes in preparations from the 6th incubation day. (aspetjournals.org)
  • patients
  • Cutler N.R., Sramek J.J., Seifert R.D., Conrad J.J., Wardle T.S. (1995) The Safety and Tolerance of Xanomeline Tartrate, an M1-Specific Cholinergic Agonist, in Patients with Alzheimer's Disease. (springer.com)
  • Patients with BHR in MCT will be treated with - in first step B2-agonist and inhaled corticosteroid (ICS) for at least 4 weeks, if improvement is not significant in next steps with leukotriene receptor antagonist (LTRA) or systemic corticosteroid. (clinicaltrials.gov)